Assessment of complications after transperineal and transrectal prostate biopsy using a risk-stratified pathway identifying patients at risk for post-biopsy infections. (2nd November 2023)

• Record Type: Journal Article
• Authors: Berg, Sebastian; Tully, Karl Heinrich; Hoffmann, Vincent; Bahlburg, Henning; Roghmann, Florian; Müller, Guido; Noldus, Joachim; Reike, Moritz
• Is Part Of: Scandinavian journal of urology. Volume 57:Number 1/6(2023)
• Page Start: 41
• Page End: 46
• Publication Date: 2023-11-02
• Subjects: MRI fusion biopsy -- transrectal biopsy -- transperineal biopsy -- post-biopsy complications -- EAU recommendations; Urology -- Periodicals; 616.6
• DOI: 10.1080/21681805.2023.2168049
• Languages: English
• ISSNs: 2168-1805

Abstract

Abstract: Introduction: Evidence of transperineal (TP) superiority over transrectal (TR) biopsy is growing due to lower infectious complication rates. However, TR biopsy is the most common procedure, and it seems that a cross-over to TP is delayed by logistical challenges such as costs, complexity, and lack of experience. We investigate whether well-selected patients without any risk factors may further undergo TR biopsy if all precautions to avoid infections are warranted. Materials and methods: Data were collected in our academic institution between August 2021 and March 2022 and after clinical implementation of the currently updated European Association of Urology guideline recommendations on the performance of prostate biopsy. Patients underwent either TP or TR biopsy according to a riskstratification based on risk factors of infectious complications. Follow-up asked for post-biopsy complications. Inverse Probability of Treatment Weighting (IPTW) propensity score was used to balance baseline characteristics. Complications were subdivided into infectious and non-infectious complications. Results: In total, 294 patients were included with 161 patients undergoing TR vs. 133 patients undergoing TP biopsy. Complication rates were 2.2% for TP vs. 5.5% for TR biopsy concerning all complications. Infectious complication rates only were 0.7% for TP vs. 1.8% for TR biopsy. After IPTW adjustment, differences were statistically significant different ( p = 0.01). Conclusion: Our study revealed that even in a well-selected patient cohort with presumably lower risk of infectious complications, TR biopsy leads to more post-biopsy complications than TP biopsy. This conclusion should motivate the urological community to switch to TP biopsy.